10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 1,001–1,100 of 1,169
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
Bays, H. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802710422 · Cited by 83
“2009 Informa UK - Curr Med Res Opin 2009; 25(3) The kidney as a target in treating diabetes Bays 675”
BackgroundInfluentialPaneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Ahrén, B., Torffvit, O., Attvall, S., Ekelund, M., Filipsson, K., Tengmark, B.-O., et al. (2015) · BMJ · doi:10.1136/bmj.h5364 · Cited by 82
Epigenetics in diabetic nephropathy, immunity and metabolism
Keating, S. T., van Diepen, J. A., Riksen, N. P., & El-Osta, A. (2018) · Diabetologia · doi:10.1007/s00125-017-4490-1 · Cited by 82
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes
MacIsaac, R. J., & Jerums, G. (2011) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2010.07.013 · Cited by 81
Erdmann, E., Harding, S., Lam, H., & Perez, A. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12608 · Cited by 80
“The 10-year follow-up of 3277 patients from the UKPDS showed modest reductions in the risk of MI and all-cause mortality in patients who received more intensive therapy in the original randomized part of the study, a so-called ‘legacy effect’ [8].”
BackgroundSemlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Furler, J., O’Neal, D., Speight, J., Manski-Nankervis, J.-A., Gorelik, A., Holmes-Truscott, E., Ginnivan, L., Young, D., Best, J., dean, et al. (2017) · BMJ · doi:10.1136/bmj.j783 · Cited by 78
Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14226 · Cited by 78
“The main randomized evidence supporting the effect of metformin on patient-level outcomes comes from the UKPDS, which demonstrated that metformin reduces the risk of diabetes-related complications, myocardial infarction and all-cause mortality compared to other early glucose-lowering therapies and diet alone, both aft…”
Kulzer, B., Daenschel, W., Daenschel, I., Schramm, W., Messinger, D., Weissmann, J., Vesper, I., Parkin, C. G., & Heinemann, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.09.002 · Cited by 77
Factors associated with weight gain in people with type 2 diabetes starting on insulin
Balkau, B., Home, P. D., Vincent, M., Marre, M., & Freemantle, N. (2014) · Diabetes Care · doi:10.2337/dc13-3010 · Cited by 77
Svensson, E., Baggesen, L. M., Johnsen, S. P., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Thomsen, R. W. (2017) · Diabetes Care · doi:10.2337/dc16-2271 · Cited by 77
“Although the large clinical randomized controlled trials have failed to show a clear beneficial effect of early intensive glycemic control on cardiovascular events in type 2 diabetes (5), long-term follow-up studies from the UK Prospective Diabetes Study (UKPDS) (8) and Veterans study (9) have suggested a beneficial c…”
BackgroundDabelea, D., Mayer-Davis, E. J., Andrews, J. S., Dolan, L. M., Pihoker, C., Hamman, R. F., Greenbaum, C., Marcovina, S., Fujimoto, W., Linder, B., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2719-6 · Cited by 76
“Limited information has been provided by interventional studies in youth with autoimmune diabetes [6–9] and individuals with adult-onset diabetes [10].”
Derosa, G., & Maffioli, P. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.012 · Cited by 76
on Behalf of the Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association, Jung, C. H., Chung, J. O., Han, K., Ko, S.-H., Ko, K. S., & Park, J.-Y. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0482-6 · Cited by 74
“Fortunately, intensive glycemic control implemented in the early stage of diabetes as well as multifactorial risk management that includes better control of high blood pressure and dyslipidemia show beneficial effects on macrovascular complications and related mortality in subjects with diabetes [6, 7].”
BackgroundUse of intensive glycemic management in older adults with diabetes mellitus
Arnold, S. V., Lipska, K. J., Wang, J., Seman, L., Mehta, S. N., & Kosiborod, M. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15335 · Cited by 74
Cassimatis, M., & Kavanagh, D. J. (2012) · Journal of Telemedicine and Telecare · doi:10.1258/jtt.2012.gth105 · Cited by 73
Cost-effectiveness of an electronic medical record based clinical decision support system
Gilmer, T. P., O'Connor, P. J., Sperl‐Hillen, J. M., Rush, W. A., Johnson, P. E., Amundson, G. H., Asche, S. E., & Ekstrom, H. L. (2012) · Health Services Research · doi:10.1111/j.1475-6773.2012.01427.x · Cited by 73
“Appropriate control of these risk factors would substantially reduce the rate of major microvascular or macrovascular diabetes-related complications and their associated costs (Patel et al. 2007; Dluhy and McMahon 2008; Gaede et al. 2008; Gerstein et al. 2008; Holman et al. 2008).”
BackgroundMethodMata‐Cases, M., Franch‐Nadal, J., Real, J., Gratacòs, M., López‐Simarro, F., Khunti, K., & Mauricio, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13045 · Cited by 72
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
“The UK Prospective Diabetes Study (UKPDS) 10-year follow-up demonstrated a possible effect on CVD as well (3).”
BackgroundCrowley, M. J., Holleman, R., Klamerus, M. L., Bosworth, H. B., Edelman, D., & Heisler, M. (2014) · Chronic Illness · doi:10.1177/1742395314523653 · Cited by 68
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66
“In a study embedded in the UKPDS, treatment of obese patients with metformin, which is not associated with weight gain or hypoglycemia, reduced the incidences of myocardial infarction and all-cause mortality (23).”
BackgroundLiu, L., Simon, B., Shi, J., Mallhi, A. K., & Eisen, H. J. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.449 · Cited by 67
Dailey, G. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.025 · Cited by 66
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Garg, S. K., Akturk, H. K., Kaur, G., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0050 · Cited by 65
Levin, K., Madsen, J. R., Petersen, I., Wanscher, C. E., & Hangaard, J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700302 · Cited by 63
Rapp, S. R., Luchsinger, J. A., Baker, L. D., Blackburn, G. L., Hazuda, H. P., Demos‐McDermott, K. E., Jeffery, R. W., Keller, J. N., McCaffery, J. M., Pajewski, N. M., et al. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14692 · Cited by 62
“After 10 years of follow-up, micro- and macrovascular benefits were apparent, despite attenuation of the glycemic benefits of the intervention.(32) In addition to a possible cognitive legacy effect, the Look AHEAD cohort, with a mean age of 69 at the time of cognitive assessment, may have just been entering the time o…”
BackgroundLindahl, J. P., Hartmann, A., Horneland, R., Holdaas, H., Reisæter, A. V., Midtvedt, K., Leivestad, T., Øyen, O., & Jenssen, T. (2013) · Diabetologia · doi:10.1007/s00125-013-2888-y · Cited by 61
Kato, S., Maruyama, S., Makino, H., Wada, J., Ogawa, D., Uzu, T., Araki, H., Koya, D., Kanasaki, K., Oiso, Y., et al. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1106-2 · Cited by 61
“Intensive glucose and blood pressure control reduces proteinuria, slows renal dysfunction and protects against microvascular complications [8, 9].”
Look AHEAD Research Group, Wing, R. R., Bray, G. A., Cassidy-Begay, M., Clark, J. M., Coday, M., Egan, C., Evans, M., Foreyt, J. P., Glasser, S., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1805 · Cited by 61
Tang, Y., Shah, H., Bueno Junior, C. R., Sun, X., Mitri, J., Sambataro, M., Sambado, L., Gerstein, H. C., Fonseca, V., Doria, A., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1842 · Cited by 60
“CAN persisted after transition to the standard glycemic control targets, which suggests a “metabolic memory” phenomenon such as that demonstrated in prior cohorts and for other diabetes complications (7,18).”
BackgroundGIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Fan, Y., Long, E., Cai, L., Cao, Q., Wu, X., & Tong, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665951 · Cited by 58
“The fi ndings of this study are important because early screening may strengthen glycemic control and reduce the risk of diabetic complications through timely monitoring of glycemia and treatment intensi fi cation (Holman et al., 2008; Colagiuri and Davies, 2009; Grif fi n et al., 2011).”
BackgroundYang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Tinetti, M. E., McAvay, G., Trentalange, M., Cohen, A. B., & Allore, H. G. (2015) · BMJ · doi:10.1136/bmj.h4984 · Cited by 58
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
Device and method for noninvasive glucose assessment
Segman, Y. (. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818763457 · Cited by 55
Griffin, S. J., Rutten, G. E. H. M., Khunti, K., Witte, D. R., Lauritzen, T., Sharp, S. J., Dalsgaard, E.-M., Davies, M. J., Irving, G. J., Vos, R. C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30349-3 · Cited by 55
A1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
“end points were still significant at 33 and 27%, respectively (11).”
BackgroundInfluentialSelf-citationCardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Lee, C. G., Schwartz, A. V., Yaffe, K., Hillier, T. A., LeBlanc, E. S., Cawthon, P. M., & the Study of Osteoporotic Fractures Research Group (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12502 · Cited by 53
Darakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
“In long-term follow-up, a 1% reduction in mean HbA1c was associated with 14% lower risk of myocardial infarction [11,16,17].”
BackgroundChen, Y.-Y., Lin, Y.-J., Chong, E., Chen, P.-C., Chao, T.-F., Chen, S.-A., & Chien, K.-L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123116 · Cited by 56
“The United Kingdom Prospective Diabetes Study (UKPDS) 10-year follow-up demonstrated that the relative benefit of having been in the group of intensive management policy, resulting in the emergence of statistically significant benefits on cardiovascular disease and all-cause death [19].”
BackgroundBain, S. C., Bekker Hansen, B., Hunt, B., Chubb, B., & Valentine, W. J. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2019.1645018 · Cited by 53
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
“A 10-year follow-up study also showed that initial intensive treatment conferred long-term benefits with respect to cardiovascular disease and mortality.(5) In that”
BackgroundDiabetes and Cardiovascular Disease Prevention in Older Adults
Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50
Makam, A. N., & Nguyen, O. K. (2017) · Circulation · doi:10.1161/circulationaha.116.022622 · Cited by 52
Simmons, R. K., Griffin, S. J., Witte, D. R., Borch-Johnsen, K., Lauritzen, T., & Sandbæk, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4323-2 · Cited by 51
Franek, E., Haluzík, M., Canecki Varžić, S., Sargin, M., Macura, S., Zacho, J., & Christiansen, J. S. (2016) · Diabetic Medicine · doi:10.1111/dme.12982 · Cited by 51
An overview of management issues in adult patients with type 2 diabetes mellitus
Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500207 · Cited by 50
Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
“diabetes-related end point, MI, and all-cause mortality persisted at 10-year follow up and were prominent among overweight patients [25].”
BackgroundEpigenetic control of variation and stochasticity in metabolic disease
Panzeri, I., & Pospisilik, J. A. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.010 · Cited by 50
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Leiter, L. A., Boras, D., & Woo, V. C. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.270 · Cited by 48
Lower extremity artery disease in patients with type 2 diabetes
Buso, G., Aboyans, V., & Mazzolai, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880044 · Cited by 48
Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0279-z · Cited by 47
“In addition to lowering hemoglobin A1C, long-term data indicate that metformin also may be associated with risk reductions in cardiovascular outcomes [4].”
BackgroundWhich treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Misra-Hebert, A. D., Pantalone, K. M., Ji, X., Milinovich, A., Dey, T., Chagin, K. M., Bauman, J. M., Kattan, M. W., & Zimmerman, R. S. (2018) · Diabetes Care · doi:10.2337/dc17-1834 · Cited by 46
“SH ED visits 3 (38) 2 (29) 2 (29) 4 (12) 3 (7) 4 (9) 7 (10) 5 (6) 4 (4) 12 (12)”
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
“1,4,133 How does SGLT2 inhibition compare?”
Viljoen, A., Hoxer, C. S., Johansen, P., Malkin, S., Hunt, B., & Bain, S. C. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13564 · Cited by 45
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy
Fechete, R., Heinzel, A., Perco, P., Mönks, K., Söllner, J., Stelzer, G., Eder, S., Lancet, D., Oberbauer, R., Mayer, G., et al. (2011) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201000136 · Cited by 45
“6 Some of these risk factors can be modified by therapy and thus current treatment regimen are directed against systemic and especially intraglomerular hypertension (blood pressure lowering medication and blockade of the renin-angiotensin-aldosterone system), as well as strict glycemic control [11-15].”
BackgroundVora, J., Cohen, N., Evans, M., Hockey, A., Speight, J., & Whately‐Smith, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12528 · Cited by 44
“Over time, escalation of glucose-lowering therapy is required in people with type 2 diabetes when glycaemic targets are no longer maintained [1], with the goal of reducing the risk of the long-term microvascular and macrovascular complications associated with chronic hyperglycaemia [2].”
BackgroundZhang, X.-W., Zhang, X.-L., Xu, B., & Kang, L.-N. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1107-1 · Cited by 44
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Two types of β-arrestin, β-arrestin-1 and β-arrestin-2, mediate the GLP-1R downstream signaling in β-cells, and also elicit the receptor internalization process. β-arrestin-1 mediates the phosphorylation of CREB and ERK1/2 [42], further phosphorylating Bad (Bcl-xL/Bcl-2-associated death promoter homolog) and inhibitin…”
BackgroundLevy, J., Cobas, R. A., & Gomes, M. B. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-16 · Cited by 44
“Metformin is recommended in International Guidelines [7,8] as first line therapy due to its favourable profile on metabolic indices of glucose, lipid and weight control [10] as well as offering protection from life threatening complications and premature mortality [11, 12 ].”
BackgroundJohnson, J. L., Slentz, C. A., Ross, L. M., Huffman, K. M., & Kraus, W. E. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00452 · Cited by 43
Qualitative study of telemonitoring of blood glucose and blood pressure in type 2 diabetes
Hanley, J., Fairbrother, P., McCloughan, L., Pagliari, C., Paterson, M., Pinnock, H., Sheikh, A., Wild, S., & McKinstry, B. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008896 · Cited by 43
“[2-4] As the prevalence of chronic conditions such as type 2 diabetes increases, it will become difficult to continue to provide the same level of healthcare staffing to manage these conditions as we do now.”
BackgroundThe evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
“Furthermore, type 2 diabetic patients have a significantly elevated cardiovascular mortality risk, which can be lowered by improved metabolic control [3, 4].”
BackgroundObesity and diabetes: the links and common approaches
Haslam, D. (2010) · Primary Care Diabetes · doi:10.1016/j.pcd.2010.04.002 · Cited by 42
“Effect described in UKPDS 80 [40], in the UKPDS 33, no significant improvements in the risk of myocardial infarction or stroke were observed after 10 years’ treatment with insulin or a sulphonylurea [41].”
BackgroundLund, S. S., Tarnow, L., Frandsen, M., Nielsen, B. B., Hansen, B. V., Pedersen, O., Parving, H.-H., & Vaag, A. A. (2009) · BMJ · doi:10.1136/bmj.b4324 · Cited by 41
“Metformin is an oral hypoglycaemic agent that targets insulin resistance. In the UK Prospective Diabetes Study (UKPDS), metformin treatment reduced the risk of cardiovascular disease in obese patients with type 2 diabetes,”
BackgroundYokoyama, H., Matsushima, M., Kawai, K., Hirao, K., Oishi, M., Sugimoto, H., Takeda, H., Minami, M., Kobayashi, M., Sone, H., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03347.x · Cited by 41
Patient empowerment and optimal glycemic control
White, R. D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.677417 · Cited by 41
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Yoshiji, S., Minamino, H., Tanaka, D., Yamane, S., Harada, N., & Inagaki, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14666 · Cited by 40
“Regarding the mechanism of action for cardiovascular and renal efficacies, it has been reported that reducing HbA1c or body weight contributes to cardiovascular, renal, and mortality risk reduction in legacy studies.(11-16) However, although cardiovascular outcome trials of GLP-1 RAs have reported an effective reducti…”
Background(2014) · Europe PMC (PubMed Central) · Cited by 40
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39
“Attaining desired blood glucose levels is a key objective in diabetes management, since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
BackgroundAhmann, A., Szeinbach, S. L., Gill, J., Traylor, L., & Garg, S. K. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0172 · Cited by 39
Lu, J., Ying, Z., Wang, P., Fu, M., Han, C., & Zhang, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15328 · Cited by 39
“15,16 These findings suggest the potential expansion of CGM indications in T2DM, highlighting the importance of conducting a systematic review.”
BackgroundMetformin and heart failure: never say never again
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.638283 · Cited by 39
“More importantly, based on an observational study of participants in a large randomised controlled trial (RCT), it confers long-term protection from all T2DMrelated endpoints, myocardial infarction and death from any cause [4].”
BackgroundJung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Chow, L. S., Zmora, R., Ma, S., Seaquist, E. R., & Schreiner, P. J. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000527 · Cited by 37
“Intensive glucose control to lower hemoglobin A1C (HbA1c) to near-normal levels has many benefits in patients with diabetes, including reduction in microvascular disease and possibly macrovascular events.(3) 5 Yet achieving this target safely while minimizing hypoglycemia remains challenging.”
BackgroundEconomic burden of hypoglycemia in patients with type 2 diabetes
Liu, S., Zhao, Y., Hempe, J. M., Fonseca, V., & Shi, L. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.87 · Cited by 37
Cai, X., Shi, L., Yang, W., Gu, S., Chen, Y., Nie, L., & Ji, L. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1570220 · Cited by 37
Zhang, Z. P., Premikha, M., Luo, M., & Venkataraman, K. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01609-2 · Cited by 36
Winkler, G., Hídvégi, T., Vándorfi, G., Balogh, S., & Jermendy, G. (2013) · Medical Science Monitor · doi:10.12659/msm.883747 · Cited by 36
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
“For example, the risk of cardiovascular complications increases with the duration of lack of adequate glycaemic control.(8,9) Diabetes is generally considered to result from either an inadequate production of insulin or a hyporesponsiveness to insulin at its receptors (‘insulin resistance’).”
BackgroundMatthews, D., Del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldánius, P. M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00926-7 · Cited by 35
Self-citationArmato, J., DeFronzo, R. A., Abdul-Ghani, M., & Ruby, R. (2012) · Endocrine Practice · doi:10.4158/ep11194.or · Cited by 35
Targeted learning with daily EHR data
Sofrygin, O., Zhu, Z., Schmittdiel, J. A., Adams, A. S., Grant, R. W., van der Laan, M. J., & Neugebauer, R. (2019) · Statistics in Medicine · doi:10.1002/sim.8164 · Cited by 35
“However, evidence supporting the effectiveness of a blanket recommendation is inconsistent across several outcomes [35, 7, 11, 17], especially when intensive anti-diabetic therapy is required.”
BackgroundAleppo, G., Hirsch, I. B., Parkin, C. G., McGill, J., Galindo, R., Kruger, D. F., Levy, C. J., Forlenza, G. P., Umpierrez, G. E., Grunberger, G., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0268 · Cited by 34
(2015) · PubMed · doi:10.6133/apjcn.2015.24.3.07 · Cited by 34
Evaluation of a new noninvasive glucose monitoring device by means of standardized meal experiments
Pfützner, A., Strobl, S., Demircik, F., Redert, L., Pfützner, J., Pfützner, A. H., & Lier, A. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818758769 · Cited by 33
Sia, H.-K., Kor, C.-T., Tu, S.-T., Liao, P.-Y., & Wang, J.-Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-81024-x · Cited by 33
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.